Valganciclovir Hydrochloride Patent Expiration
Valganciclovir Hydrochloride is Used for preventing CMV disease in high-risk kidney, heart, and kidney-pancreas transplant patients. It was first introduced by Cheplapharm Arzneimittel Gmbh
Valganciclovir Hydrochloride Patents
Given below is the list of patents protecting Valganciclovir Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Valcyte | US8889109 | Pharmaceutical dosage forms comprising valganciclovir hydrochloride | Dec 11, 2027 | Cheplapharm |
| Valcyte | US9642911 | Pharmaceutical dosage forms comprising valganciclovir hydrochloride | Dec 11, 2027 | Cheplapharm |
| Valcyte |
US6083953 (Pediatric) | 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative |
Sep 29, 2015
(Expired) | Cheplapharm |
| Valcyte | US6083953 | 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative |
Mar 29, 2015
(Expired) | Cheplapharm |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Valganciclovir Hydrochloride's patents.
Latest Legal Activities on Valganciclovir Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Valganciclovir Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Email Notification Critical
| 30 Aug, 2022 | US9642911 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 30 Aug, 2022 | US9642911 |
| Correspondence Address Change Critical
| 26 Aug, 2022 | US9642911 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 25 Aug, 2022 | US8889109 |
| Correspondence Address Change Critical
| 24 Aug, 2022 | US8889109 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 12 Apr, 2022 | US8889109 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Sep, 2020 | US9642911 |
| Surcharge for Late Payment, Large Entity | 21 Aug, 2018 | US8889109 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Aug, 2018 | US8889109 |
| Maintenance Fee Reminder Mailed Critical
| 02 Jul, 2018 | US8889109 |
Valganciclovir Hydrochloride's Family Patents
